Literature DB >> 19874654

Implications of plasma Delta9-tetrahydrocannabinol, 11-hydroxy-THC, and 11-nor-9-carboxy-THC concentrations in chronic cannabis smokers.

Erin L Karschner1, Eugene W Schwilke, Ross H Lowe, W David Darwin, Ronald I Herning, Jean Lud Cadet, Marilyn A Huestis.   

Abstract

Delta(9)-Tetrahydrocannabinol (THC) is commonly found in toxicological specimens from driving under the influence and accident investigations. Plasma cannabinoid concentrations were determined in 18 long-term heavy cannabis smokers residing on an in-patient research unit for seven days of monitored abstinence. THC, 11-hydroxy-THC, and 11-nor-9-carboxy-THC (THCCOOH) were quantified by two-dimensional gas chromatography-mass spectrometry with cryofocusing. THC concentrations were > 1 ng/mL in nine (50.0%) participants (1.2-5.5 ng/mL) on abstinence day 7. THCCOOH was detected (2.8-45.6 ng/mL) in all participants on study day 7. THC and THCCOOH median percent concentration decreases (n = 18) were 39.5% and 72.9% from day 1 to 7, respectively. Most (88.9%) of the participants had at least one specimen with increased THC compared to the previous day. Cannabis use duration and plasma THCCOOH concentrations were positively correlated on days 1-3 (R = 0.584-0.610; p = 0.007-0.011). There were no significant correlations between THC concentrations > 0.25 ng/mL and body mass index on days 1-7 (R = -0.234-0.092; p = 0.350-0.766). Measurable THC concentrations after seven days of abstinence indicate a potential mechanism for residual neurocognitive impairment observed in chronic cannabis users. THC's presence in plasma for seven days of abstinence suggests its detection may not indicate recent use in daily cannabis users.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19874654      PMCID: PMC3159863          DOI: 10.1093/jat/33.8.469

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  39 in total

1.  Potency trends of delta9-THC and other cannabinoids in confiscated marijuana from 1980-1997.

Authors:  M A ElSohly; S A Ross; Z Mehmedic; R Arafat; B Yi; B F Banahan
Journal:  J Forensic Sci       Date:  2000-01       Impact factor: 1.832

2.  Effects of chronic marijuana use on human cognition.

Authors:  R I Block; M M Ghoneim
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

3.  Simultaneous GC-EI-MS determination of Delta9-tetrahydrocannabinol, 11-hydroxy-Delta9-tetrahydrocannabinol, and 11-nor-9-carboxy-Delta9-tetrahydrocannabinol in human urine following tandem enzyme-alkaline hydrolysis.

Authors:  Tsadik T Abraham; Ross H Lowe; Stephane O Pirnay; William D Darwin; Marilyn A Huestis
Journal:  J Anal Toxicol       Date:  2007-10       Impact factor: 3.367

4.  A preliminary trial: double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence.

Authors:  Kenneth M Carpenter; David McDowell; Daniel J Brooks; Wendy Y Cheng; Frances R Levin
Journal:  Am J Addict       Date:  2009 Jan-Feb

5.  Extended urinary Delta9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure.

Authors:  Ross H Lowe; Tsadik T Abraham; William D Darwin; Ronald Herning; Jean Lud Cadet; Marilyn A Huestis
Journal:  Drug Alcohol Depend       Date:  2009-07-23       Impact factor: 4.492

6.  Intra- and intersubject whole blood/plasma cannabinoid ratios determined by 2-dimensional, electron impact GC-MS with cryofocusing.

Authors:  Eugene W Schwilke; Erin L Karschner; Ross H Lowe; Ann M Gordon; Jean Lud Cadet; Ronald I Herning; Marilyn A Huestis
Journal:  Clin Chem       Date:  2009-03-05       Impact factor: 8.327

7.  Developing limits for driving under cannabis.

Authors:  Franjo Grotenhermen; Gero Leson; Günter Berghaus; Olaf H Drummer; Hans-Peter Krüger; Marie Longo; Herbert Moskowitz; Bud Perrine; Johannes G Ramaekers; Alison Smiley; Rob Tunbridge
Journal:  Addiction       Date:  2007-10-04       Impact factor: 6.526

8.  Cannabinoid concentrations in spot serum samples 24-48 hours after discontinuation of cannabis smoking.

Authors:  Gisela Skopp; Lucia Pötsch
Journal:  J Anal Toxicol       Date:  2008-03       Impact factor: 3.367

9.  Driving under the influence of cannabis: a 10-year study of age and gender differences in the concentrations of tetrahydrocannabinol in blood.

Authors:  Alan W Jones; Anita Holmgren; Fredrik C Kugelberg
Journal:  Addiction       Date:  2008-01-08       Impact factor: 6.526

10.  Cannabis and motor function: fMRI changes following 28 days of discontinuation.

Authors:  Srinivasan S Pillay; Jadwiga Rogowska; Gen Kanayama; Staci Gruber; Norah Simpson; Harrison G Pope; Deborah A Yurgelun-Todd
Journal:  Exp Clin Psychopharmacol       Date:  2008-02       Impact factor: 3.157

View more
  28 in total

1.  Cannabinoids and metabolites in expectorated oral fluid after 8 days of controlled around-the-clock oral THC administration.

Authors:  Garry Milman; Allan J Barnes; David M Schwope; Eugene W Schwilke; Robert S Goodwin; Deana L Kelly; David A Gorelick; Marilyn A Huestis
Journal:  Anal Bioanal Chem       Date:  2011-06-03       Impact factor: 4.142

2.  Simultaneous quantification of free and glucuronidated cannabinoids in human urine by liquid chromatography tandem mass spectrometry.

Authors:  Karl B Scheidweiler; Nathalie A Desrosiers; Marilyn A Huestis
Journal:  Clin Chim Acta       Date:  2012-07-06       Impact factor: 3.786

3.  Determination of ∆-9-Tetrahydrocannabinol (THC), 11-hydroxy-THC, 11-nor-9-carboxy-THC and Cannabidiol in Human Plasma using Gas Chromatography-Tandem Mass Spectrometry.

Authors:  David M Andrenyak; David E Moody; Matthew H Slawson; Daniel S O'Leary; Margaret Haney
Journal:  J Anal Toxicol       Date:  2017-05-01       Impact factor: 3.367

Review 4.  Cannabis in sport: anti-doping perspective.

Authors:  Marilyn A Huestis; Irene Mazzoni; Olivier Rabin
Journal:  Sports Med       Date:  2011-11-01       Impact factor: 11.136

5.  Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers.

Authors:  J Hirvonen; R S Goodwin; C-T Li; G E Terry; S S Zoghbi; C Morse; V W Pike; N D Volkow; M A Huestis; R B Innis
Journal:  Mol Psychiatry       Date:  2011-07-12       Impact factor: 15.992

6.  Plasma Cannabinoid Pharmacokinetics After Controlled Smoking and Ad libitum Cannabis Smoking in Chronic Frequent Users.

Authors:  Dayong Lee; Mateus M Bergamaschi; Garry Milman; Allan J Barnes; Regina H C Queiroz; Ryan Vandrey; Marilyn A Huestis
Journal:  J Anal Toxicol       Date:  2015-10       Impact factor: 3.367

7.  Rapid Changes in CB1 Receptor Availability in Cannabis Dependent Males after Abstinence from Cannabis.

Authors:  Deepak Cyril D'Souza; Jose A Cortes-Briones; Mohini Ranganathan; Halle Thurnauer; Gina Creatura; Toral Surti; Beata Planeta; Alexander Neumeister; Brian Pittman; Marc Normandin; Michael Kapinos; Jim Ropchan; Yiyun Huang; Richard E Carson; Patrick D Skosnik
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2016-01-01

8.  Cannabinoids in exhaled breath following controlled administration of smoked cannabis.

Authors:  Sarah K Himes; Karl B Scheidweiler; Olof Beck; David A Gorelick; Nathalie A Desrosiers; Marilyn A Huestis
Journal:  Clin Chem       Date:  2013-09-17       Impact factor: 8.327

Review 9.  Cannabis effects on driving skills.

Authors:  Rebecca L Hartman; Marilyn A Huestis
Journal:  Clin Chem       Date:  2012-12-07       Impact factor: 8.327

10.  Fatty Acid Amide Hydrolase Binding in Brain of Cannabis Users: Imaging With the Novel Radiotracer [11C]CURB.

Authors:  Isabelle Boileau; Esmaeil Mansouri; Belinda Williams; Bernard Le Foll; Pablo Rusjan; Romina Mizrahi; Rachel F Tyndale; Marilyn A Huestis; Doris E Payer; Alan A Wilson; Sylvain Houle; Stephen J Kish; Junchao Tong
Journal:  Biol Psychiatry       Date:  2016-04-25       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.